Biomarin Pharmaceutical Inc. (NASDAQ: BMRN) is -6.80% lower on its value in year-to-date trading and has touched a low of $73.68 and a high of $99.56 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The BMRN stock was last observed hovering at around $91.60 in the last trading session, with the day’s loss setting it -1.74%.
Currently trading at $89.86, the stock is -0.28% and 4.10% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 3.74 million and changing -1.89% at the moment leaves the stock 2.80% off its SMA200. BMRN registered -3.41% loss for a year compared to 6-month loss of 4.46%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 11.67% gain in the last 1 month and extending the period to 3 months gives it a 13.62%, and is -0.66% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 2.87% over the week and 2.48% over the month.
Biomarin Pharmaceutical Inc. (BMRN) has around 3401 employees, a market worth around $17.11B and $2.59B in sales. Current P/E ratio is 67.84 and Fwd P/E is 29.68. Profit margin for the company is 9.91%. Distance from 52-week low is 21.97% and -9.74% from its 52-week high. The company has generated returns on investments over the last 12 months (4.36%).
Biomarin Pharmaceutical Inc. quarterly earnings per share for the current quarter are estimated at 0.53 with sales reaching $703.47M over the same period.The EPS is expected to grow by 134.28% this year, but quarterly earnings will post 15.80% year-over-year. Quarterly sales are estimated to grow 15.60% in year-over-year returns.
849.0 institutions hold shares in Biomarin Pharmaceutical Inc. (BMRN), with institutional investors hold 100.67% of the company’s shares. The shares outstanding are 188.60M, and float is at 187.98M with Short Float at 3.54%. Institutions hold 99.79% of the Float.
The top institutional shareholder in the company is BLACKROCK INC. with over 22.74 million shares valued at $1.87 billion. The investor’s holdings represent 12.0394 of the BMRN Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 18.99 million shares valued at $1.56 billion to account for 10.0569 of the shares outstanding. The other top investors are PRIMECAP MANAGEMENT CO/CA/ which holds 18.79 million shares representing 9.9489 and valued at over $1.55 billion, while DODGE & COX holds 7.3759 of the shares totaling 13.93 million with a market value of $1.15 billion.
Biomarin Pharmaceutical Inc. (BMRN) Insider Activity
The most recent transaction is an insider sale by Burkhart Erin, the company’s GVP, Chief Accounting Officer. SEC filings show that Burkhart Erin sold 714 shares of the company’s common stock on Aug 13 ’24 at a price of $90.00 per share for a total of $64260.0. Following the sale, the insider now owns 14449.0 shares.
Still, SEC filings show that on May 30 ’24, Mueller Brian (EVP, Chief Financial Officer) disposed off 5,000 shares at an average price of $75.19 for $0.38 million. The insider now directly holds 72,159 shares of Biomarin Pharmaceutical Inc. (BMRN).
